שוק מדעי החיים Life Sciences Newsflash
 
 
הקלק על התחום המעניין אותך על מנת לקרוא על ההתפתחויות החדשות כפי שהופיעו לאחרונה במחקרי שוק עולמיים:
Drugs Regulators Commercial Focus RNA Interference Dyslipidemia Advanced Technologies Infectious Companion Diagnostics Hepatitis Cancer Urology and Gender-Specific Health Cardiovascular
 
 Drugs 
Companies and Technologies
From: Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
This is a is a new report published by Business Insights that examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations. Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their most successful strategies.
 
 Regulators 
Competition Law and Intellectual Property
Written by the leading-edge experts the report will provide you with a succinct but comprehensive overview on IP and Competition Law matters. Leading cases involving GlaxoSmithKline, Boehringer Ingelheim, Bayer, Organon, Johnson & Johnson, AstraZeneca, Napp Pharmaceuticals and Genzyme illustrate the key points made. This report examines the complex inter-relating issues of regulation, intellectual property and competition law specific to the pharmaceuticals sector and provides a practical guide to these fields.
From: Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector
The report includes including the following: How legislation and case law has set out limits in various areas on the extent to which intellectual property can be enforced in the pharmaceuticals sector; The use of intellectual property to control parallel imports and the impact of the EC rules on free circulation of goods; Circumstances when the enforcement of intellectual property could infringe EC competition law; The application of the EC competition rules to agreements and conduct restricting parallel imports and exports; Case law and abuse of dominant position on pricing issues; The EC competition regime in relation to R&D collaboration agreements and technology licensing agreements - which types of provisions can be included and when, and which should be avoided; The EC competition regime in relation to vertical agreements in the pharmaceuticals sector including agency, distribution, co-marketing and co-promoting agreements, and which provisions should and should not be included; The state of play on damages claims under the competition rules against cartels and abuse of dominance.
 
 Commercial Focus 
Biotechnology Companies
From: The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
This is a new report published by that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biopharmaceutical companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry. Use key indicators to assess the performances of the fastest growing biopharma companies, benchmark their most successful strategies and understand major industrial issues with this new report.
 
 RNA Interference 
Market Overview
Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies.
From: RNA Interference Markets
RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing.
 
 Dyslipidemia 
New Opportunities
Dyslipidemia, a highly prevalent, key modifiable risk factor for atherosclerosis and cardiovascular disease, continues to offer potentially lucrative rewards despite the prevailing competitive environment. The maturing market for agents that reduce low-density lipoprotein cholesterol (LDL) creates new opportunities for agents that target other lipid abnormalities, such as low levels of high-density lipoprotein cholesterol (HDL). Following the discontinuation of Pfizer’s CETP inhibitor, torcetrapib, there remains substantial unmet need for novel therapies that provide antiatherogenic benefits, and several approaches are being investigated.
From: Dyslipidemia
Questions Answered in This Report: Physicians are placing greater emphasis on achieving aggressive LDL targets in high-risk patients. How will this trend affect the use of polypharmacy and prescribing of fixed-dose combinations (FDCs)? Physicians debated the merit of the ENHANCE trial at the 2008 meeting of the American College of Cardiology. What is the impact of this study? Disappointing Phase III trial results with torcetrapib have prompted the medical community to reappraise prospects for remaining emerging CETP inhibitors and to consider other approaches to treat low HDL. What are some of the new approaches under investigation, what approval hurdles are future HDL-modifying therapies likely to face, and what are the prospects for the most advanced HDL therapies in development?
 
 Advanced Technologies 
Patient Monitoring Systems
is no longer satisfactory for a system to simply monitor a patient's vital signs. Advances in remote patient monitoring include new peripherals, real-time audio and video for “face-to-face” interaction between clinicians and patients, wireless communication, systems that “sort” the vast amount of data collected in order to put it into the context of a patient’s condition, portable and ambulatory monitors, web-based access to the patient record, systems that transfer data to an electronic medical record (EMR), and full-service outsourcing that includes a clinician to evaluate data and send a report to the attending physician.
From: High-Tech Patient Monitoring Systems Markets (Remote and Wireless, Patient Data Processing, EMR Data transfer/interface Systems)
Patient data processing applications and equipment use algorithms to evaluate monitoring measurements for a patient’s specific condition(s). Usually, these can be customized by the physician, with reports sent to the physician; these can be integrated parts of a PM system or add-ons. EMR data transfer equipment and applications for this report are either components of, or add-ons to, patient monitoring systems. This does not include EMR applications, simply the applications in this segment transfer data to third-party EMRs.
 
 Infectious 
Community-Acquired
Despite the availability of numerous antibiotic agents, pneumonia is a leading cause of morbidity and mortality worldwide. The majority of cases of community-acquired pneumonia (CAP) are treated in the outpatient setting; however, severe cases that require inpatient treatment incur costs 20-50 times greater than outpatient treatment. CAP is an important infection for antibiotic drug developers because it can be a gateway indication to the large, outpatient respiratory tract infections market as well as an indication with a sizable inpatient population. With sales of the 7-valent pneumococcal conjugate vaccine (Wyeth’s Prevnar) surpassing $1 billion in the United States alone in 2006, the vaccine market is highly lucrative, with potential for expansion for the companies involved.
From: Community-Acquired Pneumonia
Scope: Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan; Primary research: 81 country-specific interviews with infectious disease specialists, primary care physicians, critical care specialists, pulmonologists, and microbiologists; Epidemiology: Inpatient and outpatient CAP diagnosed and drug-treated populations, hospital discharges among patients with pneumonia due to specific pathogens, such as S. pneumoniae, H. influenzae, atypical pathogens, and S. aureus; Population segments in market forecast: Inpatient, outpatient, pediatric vaccines, and adult vaccines; Emerging therapies: Phase II: 5 drugs; Phase III: 7 drugs and 2 vaccines; preregistration: 2 drugs. Coverage of 11 select preclinical and Phase I products; Market forecast features: Bottom-up, patient-based forecast of the inpatient, outpatient, adult vaccine, and pediatric vaccine market, by drug, through 2016.
 
 Companion Diagnostics 
Future Outlook
Diagnostics can be used to identify subgroups of patients who may or may not benefit from a companion drug, who may have adverse reactions to that drug, or who may require different doses of that drug because of their particular metabolic activity. The concept of companion diagnostics as an integral component of personalized medicine--RxDx--is an emerging and critical paradigm for drug development and use. What is driving that paradigm.
From: The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends
Get the Answers You Need to Shape Your Strategy: More than a dozen companion diagnostic tests are approved for use in the United States and guide the prescription of products in oncology, cardiovascular disease, and infectious diseases. What are the most successful RxDx products, and will their success encourage further development? Why are companies reluctant to abandon the blockbuster model in favor of personalized medicine? Personalized medicine continues to be heavily debated within the industry, and future growth depends on more attention from all stakeholders. What is each stakeholder’s role in RxDx collaborations, and how can these collaborations drive development? What does each player have to offer the others to encourage development and reconcile debate? Why are parallel development programs critical? Reimbursement issues are an important factor that will determine whether the pharmaceutical industry is willing to invest in RxDx, but current reimbursement policies can be discouraging. What evidence must companies provide to third-party payers to demonstrate value and ensure reimbursement? What are the policies and issues surrounding reimbursement? With few RxDx products on the market and even fewer reimbursed, how can R&D costs ever be recovered?
 
 Hepatitis  
Hepatitis B
Due to their good safety profile and increasing efficacy, antivirals will expand their lead as the dominant drug class for HBV treatment. Particularly Bristol-Myer Squibb's Baraclude (entecavir) will experience a rapid uptake. Interferons will benefit from increased diagnosis rates and combination therapy, but their overall use will remain limited. Launch of Gilead's tenofovir, already marketed for HIV and currently in Phase III trials for HBV, is expected for 2008. Driven by its excellent efficacy, safety and resistance profile, tenofovir will replace entecavir as the market leader by 2013, reaching peak sales of up to $400m across the 7MM.
From: Commercial and Pipeline Insight: Hepatitis B - Improved antivirals drive rapid market growth
Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.
 
 Cancer 
Therapeutics
Cancer is the second leading cause of death by disease in the United States, exceeded only by heart disease. Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors. Pharmaceutical and biotechnology companies are investing billions of dollars to search out and develop weapons for the arsenal in the war against cancer.
From: Cancer Therapeutics Markets
This report provides an overview of the global market for cancer therapeutics. The examination focuses on the efforts of biotechnology companies and pharmaceutical firms to incorporate new technologies for developing anti-cancer drugs into their corporate strategies. This study examines cancer therapeutic products now on the market, as well as those currently under development that might be commercialized in the near future. Additionally, the report profiles a number of firms that are actively involved in marketing and developing of products to be used in the treatment of cancer-both large multinational corporations. The analysis also provides an overview of the disease and data on cancers by site or type. It provides incidence and mortality data for different types of the disease. In addition, the report provides a summary of each of the therapies that are being used to treat cancer.
 
 Urology and Gender-Specific Health 
Non-hormonal Treatments for Menopausal Symptoms
The key opportunity for non-hormonal treatments lies in capturing sales that have been lost by the hormonal treatments since the WHI results. Despite increased demand, the current R&D pipeline for non-hormonals is small and lacks innovation. Wyeth's Pristiq could be first to market although regulatory delays indicate possible non-approval. Returning confidence in HRT among gynecologists and the recent upturn in sales of these therapies represents a growing barrier to entry for non-hormonal drug companies. Nevertheless, prevailing mistrust of HRT among primary care physicians (PCPs) and eligible patients represents a key market opportunity for non-hormonals.
From: Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.
 
 Cardiovascular 
Percutaneous Coronary Intervention
Since the introduction of PCI the procedure rate has increased dramatically making it one of the most common interventional procedures for heart disease. Use of PCI differs across the major markets, with this more aggressive revascularization strategy receiving greatest uptake in the United States, where coronary artery disease is most prevalent. Evidence that facilitated PCI improves clinical outcomes remains inconclusive, although opinion leaders consider the premature interruption of ASSENT-4 to advise against facilitation with thrombolytics; the ACC/AHA guidelines suggest facilitation only in "high risk" patients, whereas the ESC say they find no evidence to recommend it at all.
From: Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: "in-stent thrombosis". Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.
 
Full industries index
Biotechnology: Agriculture GMO, Antibody Technologies, Antisense Technology, Biomaterials, Biopharmaceuticals, Drug Discovery, Emerging Technology, Environmental/Industrial Biotechnology, Enzymes, Gene Therapy, Genetic Engineering, Genomics, Informatics, Instrumentation & Equipment, Molecular Biology, Proteomics, Regulation & Bioethics, Tissue Engineering, Wound Care
Medical Imaging: Computed Tomography, Contrast Media, Digital Radiography, General, Interventional Radiology, Mammography, NMR & MRI, Nuclear Medicine, PACS (Picture Archiving Computer Systems), PET (Positron Emission Tomography)
Medical Devices: Anesthesia, Blood, Cardiovascular Devices, Catheters, Company Reports, Critical Care, Dental Equipment, Diabetes, Dialysis, Disposables, Drug Delivery, Durable Medical Equipment, Electronics, Equipment & Supplies, General, Home Health, Information Technology, Infusion Products, Manufacturing & Packaging, Materials Science, Minimally Invasive Surgery, Needles, Syringes, IV Access, Ophthalmic Devices, Orthopedics, Regulation, Respiratory Devices, Surgical Equipment, Urology, Wound Care
להרשמה לעדכונים לחצו כאן; להסרה מרשימת התפוצה לחצו כאן
© אדקיט ישראל בע"מ. 2008